首页> 美国卫生研究院文献>Scientific Reports >The S. aureus 4-oxalocrotonate tautomerase SAR1376 enhances immune responses when fused to several antigens
【2h】

The S. aureus 4-oxalocrotonate tautomerase SAR1376 enhances immune responses when fused to several antigens

机译:当与几种抗原融合时金黄色葡萄球菌4-草酰巴豆酸酯互变异构酶SAR1376增强免疫反应

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

A persistent goal of vaccine development is the enhancement of the immunogenicity of antigens while maintaining safety. One strategy involves alteration of the presentation of the antigen by combining antigens with a multimeric scaffold. Multi-antigen vaccines are under development, and there are presently far more candidate antigens than antigen scaffolding strategies. This is potentially problematic, since prior immunity to a scaffold may inhibit immune responses to the antigen-scaffold combination. In this study, a series of domains from S. aureus which have been shown to crystallise into multimeric structures have been examined for their scaffolding potential. Of these domains, SAR1376, a 62 amino acid member of the 4-oxalocrotonate tautomerase (4-OT) family, was pro-immunogenic in mice when fused to a range of pathogen antigens from both S. aureus and P. falciparum, and delivered by either DNA vaccination, viral vector vaccines or as protein-in-adjuvant formulations. The adjuvant effect did not depend on enzymatic activity, but was abrogated by mutations disrupting the hexameric structure of the protein. We therefore propose that SAR1376, and perhaps other members of the 4-OT protein family, represent very small domains which can be fused to a wide range of antigens, enhancing immune responses against them.
机译:疫苗开发的一个持久目标是在保持安全性的同时提高抗原的免疫原性。一种策略涉及通过将抗原与多聚支架结合来改变抗原的呈递。多抗原疫苗正在开发中,目前候选抗原远远超过抗原支架策略。这是潜在的问题,因为先前对支架的免疫可能抑制对抗原-支架组合的免疫反应。在这项研究中,对金黄色葡萄球菌的一系列结构域的支架潜力进行了研究,这些结构域已显示结晶为多聚体结构。在这些结构域中,SAR1376是4-草酸巴豆酸互变异构酶(4-OT)家族的62个氨基酸,当与多种金黄色葡萄球菌和恶性疟原虫的病原体抗原融合并转运时,它们在小鼠中具有促免疫原性。通过DNA疫苗接种,病毒载体疫苗或作为佐剂蛋白配制。佐剂作用不依赖于酶促活性,而是被破坏蛋白质六聚体结构的突变所废除。因此,我们建议SAR1376以及4-OT蛋白家族的其他成员,代表非常小的域,可以与多种抗原融合,从而增强针对它们的免疫应答。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号